X

Trial Profile

A study assessing the combination of tazemetostat with R-CHOP regimen in follicular lymphoma patients

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 10 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tazemetostat (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
Indications Follicular lymphoma
Focus Therapeutic Use

Most Recent Events

06 May 2021 Status changed from planning to recruiting, according to an Epizyme media release.
14 Aug 2019 New trial record
09 Aug 2019 According to a Epizyme media release, this study will be conducted in collaboration with the Lymphoma Study Association and is anticipated to begin in the second half of 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com